Answers are grounded in this paper and cite their sources.
At week 48 in the phase IIIb DAWNING study, the integrase strand transfer inhibitor (INSTI) dolutegravir plus 2 nucleoside reverse transcriptase inhibitors demonstrated superiority to ritonavir-boosted lopinavir in achieving virologic suppression in adults with HIV-1 who failed first-line therapy. Here, we report emergent HIV-1 drug resistance and mechanistic underpinnings among dolutegravir-treated adults in DAWNING.
No takes yet. Share an insight, caveat, or question.
A 2021 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: